Market immaturity and regulatory compliance risks in the digital currency business
First written in FY2018. 17 of 28 entries say "Worsened", first in FY2019-Q3. Latest entry: 2026-11-06.
No other company in this theme has enough history to compare yet.
- FY2026WorsenedAnnual report
「Including a ¥816 million loss related to ディーカレットホールディングス, compared with a ¥553 million loss in the same period of the previous year, and other items, the result was a ¥474 million loss, compared with a ¥414 million loss in the same period of the previous year.」
The equity-method loss related to the digital currency business increased from ¥553 million in the same period of the previous year to ¥816 million, and cumulative equity-method losses totaled ¥7.2 billion as of 31 March 2026. - FY2026-H1WorsenedAnnual report
「For the six-month interim period, equity-method investment income/loss included a ¥355 million loss related to ディーカレットホールディングス, compared with a ¥158 million loss in the same period of the previous year, and other items, resulting in a ¥226 million loss, compared with a ¥91 million loss in the same period of the previous year.」
The loss at ディーカレットホールディングス related to the digital currency business increased from ¥158 million in the same period of the previous year to ¥355 million, and the overall equity-method investment loss also increased from ¥91 million to ¥226 million. - FY2025-H1MitigatedAnnual report
「For the six-month interim period, equity-method investment income/loss included a ¥158 million loss related to ディーカレットホールディングス, including a ¥209 million gain from changes in our equity interest due to a capital increase, and other items, resulting in a ¥91 million loss, compared with a ¥273 million loss in the same period of the previous year.」
Although an equity-method loss related to ディーカレット remained, the overall equity-method investment loss narrowed from ¥273 million in the same period of the previous year to ¥91 million. - FY2024WorsenedAnnual report
「For the fiscal year, equity-method investment income/loss included a ¥535 million loss related to ディーカレットホールディングス, compared with a ¥382 million loss in the same period of the previous year, and other items, resulting in a ¥465 million loss, compared with a ¥204 million loss in the same period of the previous year.」
The loss related to ディーカレット increased from ¥382 million to ¥535 million, and the overall equity-method investment loss also increased. - FY2024-Q3WorsenedAnnual report
「For the nine months ended the third quarter, equity-method investment income/loss included a ¥392 million loss related to ディーカレットホールディングス, compared with a ¥274 million loss in the same period of the previous year, and other items, resulting in a ¥422 million loss, compared with a ¥161 million loss in the same period of the previous year.」
The loss related to ディーカレットホールディングス increased from ¥274 million in the same period of the previous year to ¥392 million, and the overall equity-method investment loss also increased from ¥161 million to ¥422 million. - FY2024-Q2WorsenedAnnual report
「For the six months ended the second quarter, equity-method investment income/loss included a ¥249 million loss related to ディーカレットホールディングス, compared with a ¥180 million loss in the same period of the previous year, and other items, resulting in a ¥273 million loss, compared with a ¥78 million loss in the same period of the previous year.」
The loss related to ディーカレットホールディングス increased from ¥180 million in the same period of the previous year to ¥249 million, and the overall equity-method investment loss also increased from ¥78 million to ¥273 million. - FY2024-Q1WorsenedAnnual report
「For the three months ended the first quarter, equity-method investment income/loss included a ¥125 million loss related to ディーカレットホールディングス, compared with a ¥78 million loss in the same period of the previous year, and other items, resulting in a ¥154 million loss, compared with a ¥14 million loss in the same period of the previous year.」
The loss related to ディーカレットホールディングス increased from ¥78 million in the same period of the previous year to ¥125 million, and the overall equity-method investment loss also increased from ¥14 million to ¥154 million. - FY2023WorsenedAnnual report
「We have invested a cumulative ¥7,082 million in ディーカレット, representing a 38.2% equity interest. As of 31 March 2023, the cumulative equity-method loss was ¥5,336 million. In March 2023, we also subscribed for ¥2 billion of unsecured straight bonds issued by ディーカレットDCP, with a 10-year maturity.」
The digital currency business remained in the start-up phase even after the sale of the crypto asset business. Disclosure of cumulative equity-method losses of ¥5,336 million and a ¥2 billion bond subscription clarified the exposure to investment and additional support. - FY2023-Q3MitigatedAnnual report
「For the nine months ended the third quarter, equity-method investment income/loss included a ¥274 million loss related to ディーカレットホールディングス, compared with ¥1,332 million in the same period of the previous year, and other items, resulting in a ¥161 million loss, compared with a ¥1,056 million loss in the same period of the previous year.」
Losses related to ディーカレットホールディングス and the overall equity-method investment loss both narrowed from the same period of the previous year. However, losses continued. - FY2023-Q2MitigatedAnnual report
「For the six months ended the second quarter, equity-method investment income/loss included a ¥180 million loss related to ディーカレットホールディングス and other items, resulting in a ¥78 million loss, compared with a ¥372 million loss in the same period of the previous year.」
Although losses related to ディーカレットホールディングス continued, the overall equity-method investment loss narrowed from ¥372 million in the same period of the previous year to ¥78 million. - FY2023-Q1MitigatedAnnual report
「For the three months ended the first quarter, equity-method investment income/loss included a ¥78 million loss related to ディーカレットホールディングス and other items, resulting in a ¥14 million loss, compared with a ¥217 million loss in the same period of the previous year.」
Although losses related to ディーカレットホールディングス continued, the overall equity-method investment loss narrowed from ¥217 million in the same period of the previous year to ¥14 million. - FY2022-Q3WorsenedAnnual report
「Equity-method investment loss for the cumulative third-quarter consolidated period was ¥1,056 million, compared with a loss of ¥727 million in the same period of the previous year. This included an equity-method loss of ¥1,332 million relating to DeCurret Holdings, Inc., including a ¥484 million loss recognized in connection with the sale of the crypto-asset business dated 1 February 2022.」
The equity-method loss related to ディーカレット was ¥1,332 million, and the overall equity-method investment loss increased from ¥727 million in the same period of the previous year. A ¥484 million loss related to the sale of the crypto asset business was also recognized. - FY2022-Q2MitigatedAnnual report
「For the six months ended the second quarter, equity-method investment income/loss included a ¥552 million loss related to ディーカレット and other items, resulting in a ¥372 million loss, compared with a ¥413 million loss in the same period of the previous year.」
Although losses related to ディーカレット continued, the overall equity-method investment loss narrowed from ¥413 million in the same period of the previous year to ¥372 million. - FY2022-Q1MitigatedAnnual report
「For the three months ended the first quarter, equity-method investment income/loss included a ¥296 million loss related to ディーカレット and other items, resulting in a ¥217 million loss, compared with a ¥279 million loss in the same period of the previous year.」
Although losses related to ディーカレット continued, the overall equity-method investment loss narrowed from ¥279 million in the same period of the previous year to ¥217 million. - FY2021-Q3WorsenedAnnual report
「For the nine months ended the third quarter, equity-method investment income/loss included a ¥785 million loss related to ディーカレット and other items, resulting in a ¥727 million loss, compared with a ¥367 million loss in the same period of the previous year.」
The loss related to ディーカレット was ¥785 million, and the overall equity-method investment loss increased from ¥367 million in the same period of the previous year to ¥727 million. - FY2021-Q2WorsenedAnnual report
「For the six months ended the second quarter, equity-method investment income/loss included a ¥578 million loss related to ディーカレット and other items, resulting in a ¥413 million loss, compared with a ¥133 million loss in the same period of the previous year.」
The loss related to ディーカレット was ¥578 million, and total equity-method investment income/loss was also a ¥413 million loss. - FY2021-Q1MitigatedAnnual report
「Including a ¥306 million loss related to ディーカレット and other items, the result was a ¥279 million loss.」
The equity-method investment loss related to ディーカレット was ¥306 million, down from the ¥337 million recognized as our share in the same period of the previous year. However, investment losses associated with the digital currency business continued to occur. - FY2020-Q3WorsenedAnnual report
「For the nine months ended the third quarter, equity-method investment income/loss included a ¥602 million equity-method investment loss related to ディーカレット and other items, resulting in a ¥367 million loss, compared with a ¥67 million loss in the same period of the previous year.」
Including the ¥602 million equity-method investment loss related to ディーカレット, total equity-method investment income/loss was a ¥367 million loss. The loss increased from ¥133 million in the cumulative period through the previous quarter. - FY2020-Q2WorsenedAnnual report
「For the six months ended the second quarter, equity-method investment income/loss included recognition of ¥685 million as our share of ディーカレット’s loss for the period and a ¥376 million gain from changes in our equity interest due to ディーカレット’s capital increase, resulting in a ¥133 million loss.」
The recognized equity-method investment loss related to ディーカレット was ¥685 million, up from ¥337 million in the cumulative period through the previous quarter. Even including the ¥376 million gain from changes in our equity interest due to the capital increase and other items, equity-method investment income/loss was a ¥133 million loss. - FY2020-Q1MaterialisedAnnual report
「Equity-method investment income for the three months ended the first quarter of the current consolidated fiscal year was ¥112 million, compared with a loss of ¥30 million in the same period of the previous year. This included recognition of the company’s ¥337 million share of 株式会社ディーカレット’s loss for the period and a ¥374 million gain from changes in equity interests resulting from 株式会社ディーカレット’s capital increase.」
We recognized ¥337 million as our share of ディーカレット’s loss for the period, and the investment loss risk associated with the immature market and business launch continued to materialize. However, including a ¥374 million gain from changes in our equity interest due to a capital increase and other items, total equity-method investment income was ¥112 million. - FY2019MaterialisedAnnual report
「Equity-method investment income for the current consolidated fiscal year resulted in a loss of ¥318 million, including an equity-method investment loss of ¥503 million related to 株式会社ディーカレット.」
The investment loss risk associated with the immature market and unsuccessful launch of the digital currency business materialized as an equity-method investment loss of ¥503 million related to ディーカレット. - FY2019-Q3WorsenedAnnual report
「Equity-method investment income for the nine months ended the third quarter of the current consolidated fiscal year resulted in a loss of ¥69 million, including an equity-method investment loss of ¥272 million related to 株式会社ディーカレット.」
The equity-method investment loss related to ディーカレット increased to ¥272 million from ¥148 million in the cumulative period through the previous quarter. - FY2019-Q2MaterialisedAnnual report
「Equity-method investment income for the six months ended the second quarter of the current consolidated fiscal year resulted in a loss of ¥23 million, including an equity-method investment loss of ¥148 million related to 株式会社ディーカレット.」
In connection with the previously disclosed risk of greater-than-expected equity-method investment losses in the digital currency business, an equity-method investment loss of ¥148 million related to ディーカレット was actually recognized. - FY2018First statedAnnual report
「The market for digital currency trading and settlement is immature and still developing, and competition is also expected to intensify. If the company’s business does not launch or grow as expected, we may incur greater-than-expected equity-method investment losses or impairment losses, or may need to provide additional funding.」
The company newly disclosed risks associated with its investment in ディーカレット as part of the digital currency business, including an immature market, intensifying competition, an unsuccessful business launch, the possibility of additional funding, and impairment losses.